Publication Details

Category Text Publication
Reference Category Preprints
DOI 10.21203/
Licence creative commons licence
Title (Primary) Artefactual source of 2-hydroxypyridine
Author Wilmes, P.; Trezzi, J.-P.; Aho, V.; Jäger, C.; Schade, S.; Janzen, A.; Hickl, O.; Kunath, B.; Thomas, M.; Schmit, K.; Garcia, P.; Sciortino, A.; Martin-Gallausiaux, C.; Halder, R.; Huarte, O.U.; Heurtaux, T.; Heins-Marroquin, U.; Gomez-Giro, G.; Weidenbach, K.; Delacour, L.; Laczny, C.; Novikova, P.; Ramiro-Garcia, J.; Singh, R.; Andújar, B.T.; Lebrun, L.; Daujeumont, A.; Habier, J.; Dong, X.; Gavotto, F.; Heintz-Buschart, A.; Schneider, J.; Jehmlich, N. ORCID logo ; von Bergen, M.; Schymanski, E.; Schmitz, R.; Schwamborn, J.; Glaab, E.; Linster, C.; Kitami, T.; Buttini, M.; May, P.; Trenkwalder, C.; Oertel, W.; Mollenhauer, B.
Source Titel Research Square
Year 2023
Department MOLSYB
Language englisch
Topic T9 Healthy Planet

As part of the revisions of our original manuscript, we performed 13C-labelling experiments with cultures of the microorganism most strongly correlated with 2-hydroxypyridine (2-HP), i.e. the archaeal species Methanobrevibacter smithii. Although unlabelled 2-HP was detected in the cultures, the measurements by gas chromatography-mass spectrometry (GC-MS) indicated that M. smithii was not the direct source of 2-HP as labelled 2-HP was not measured. Further experiments involving a labelled solvent (deuterated pyridine) and faecal samples from our original study alongside the use of additional analytical platforms and measurements on human blood plasma and mouse brain tissues demonstrate that 2-HP is an artefact of the measurements by GC-MS. It is produced in a sample-specific manner during the derivatisation process for GC-MS by a so far unknown chemical reaction. Our correlative links between archaea (M. smithii) and 2-HP remain but, based on these most recent results, cannot be directly mechanistically linked. Apart from this central limitation of our original study, we have so far not uncovered any reasons which would draw into question the validity of our in vitro and in vivo results linking 2-HP to the observed molecular, behavioural and pathological hallmarks of Parkinson’s disease.

Persistent UFZ Identifier
Wilmes, P., Trezzi, J.-P., Aho, V., Jäger, C., Schade, S., Janzen, A., Hickl, O., Kunath, B., Thomas, M., Schmit, K., Garcia, P., Sciortino, A., Martin-Gallausiaux, C., Halder, R., Huarte, O.U., Heurtaux, T., Heins-Marroquin, U., Gomez-Giro, G., Weidenbach, K., Delacour, L., Laczny, C., Novikova, P., Ramiro-Garcia, J., Singh, R., Andújar, B.T., Lebrun, L., Daujeumont, A., Habier, J., Dong, X., Gavotto, F., Heintz-Buschart, A., Schneider, J., Jehmlich, N., von Bergen, M., Schymanski, E., Schmitz, R., Schwamborn, J., Glaab, E., Linster, C., Kitami, T., Buttini, M., May, P., Trenkwalder, C., Oertel, W., Mollenhauer, B. (2023):
Artefactual source of 2-hydroxypyridine
Research Square 10.21203/